Core Insights - Vivani Medical, Inc. is developing miniature, ultra long-acting GLP-1 implants for chronic weight management and type 2 diabetes, with topline data from the LIBERATE-1 clinical trial expected in mid-2025 [1][2][3] Company Overview - Vivani Medical utilizes its proprietary NanoPortal platform to create therapeutic implants that deliver drug molecules steadily over extended periods, aiming to improve patient adherence and tolerance [3] - The company's lead programs include NPM-139 (semaglutide implant) and NPM-115 (exenatide implant), designed for once or twice-yearly administration for chronic weight management [3] - Vivani is also developing NPM-119, a six-month subdermal GLP-1 implant for type 2 diabetes treatment, and is considering a semaglutide implant for the same condition [3] Clinical Trial Information - The LIBERATE-1 trial is a first-in-human study of the NPM-115 implant, with results anticipated in mid-2025 [2][3] - The company is actively engaging with investors and stakeholders through events such as a virtual fireside chat scheduled for April 24, 2025 [2] Industry Context - Medication non-adherence affects approximately 50% of patients, contributing to over $500 billion in annual avoidable healthcare costs and 125,000 preventable deaths in the U.S. [4] - Vivani's differentiated portfolio of GLP-1 implants aims to address the challenges of medication adherence faced by patients with obesity and type 2 diabetes [4]
Vivani Medical to Participate in Virtual Fireside Chat Hosted by H.C. Wainwright & Company